These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review. Liya G; Yuguang W; Jian L; Huaiping Y; Xue H; Jianwei H; Jiaju M; Youran L; Chen M; Yiqing J APMIS; 2020 Jun; 128(6):423-432. PubMed ID: 32363707 [TBL] [Abstract][Full Text] [Related]
43. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. Bchetnia M; Girard C; Duchaine C; Laprise C J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421 [TBL] [Abstract][Full Text] [Related]
44. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future]. Ye ZW; Jin DY Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053 [TBL] [Abstract][Full Text] [Related]
45. Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders? Murta V; Villarreal A; Ramos AJ ASN Neuro; 2020; 12():1759091420954960. PubMed ID: 32878468 [TBL] [Abstract][Full Text] [Related]
46. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S Front Immunol; 2020; 11():1949. PubMed ID: 32849654 [TBL] [Abstract][Full Text] [Related]
47. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Hui KPY; Cheung MC; Perera RAPM; Ng KC; Bui CHT; Ho JCW; Ng MMT; Kuok DIT; Shih KC; Tsao SW; Poon LLM; Peiris M; Nicholls JM; Chan MCW Lancet Respir Med; 2020 Jul; 8(7):687-695. PubMed ID: 32386571 [TBL] [Abstract][Full Text] [Related]
48. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Martinez MA Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082 [TBL] [Abstract][Full Text] [Related]
50. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK Front Immunol; 2020; 11():1880. PubMed ID: 32973779 [TBL] [Abstract][Full Text] [Related]
51. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Wooding DJ; Bach H Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241 [TBL] [Abstract][Full Text] [Related]
52. [Coagulopathy and thrombosis: similarities and differences among pathogenic coronaviruses]. Páramo JA An Sist Sanit Navar; 2020 Aug; 43(2):245-249. PubMed ID: 32814926 [TBL] [Abstract][Full Text] [Related]
53. Current epidemiological and clinical features of COVID-19; a global perspective from China. Tu H; Tu S; Gao S; Shao A; Sheng J J Infect; 2020 Jul; 81(1):1-9. PubMed ID: 32315723 [TBL] [Abstract][Full Text] [Related]
54. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797 [TBL] [Abstract][Full Text] [Related]
55. A Commentary on "A comparative overview of COVID-19, MERS and SARS: Review article" (International Journal of Surgery 2020; 81:1-8). Awais S; Shah SFH; Shah SGS Int J Surg; 2020 Nov; 83():28-29. PubMed ID: 32927142 [No Abstract] [Full Text] [Related]
56. Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients? Gandhi S; Srivastava AK; Ray U; Tripathi PP ACS Chem Neurosci; 2020 May; 11(10):1379-1381. PubMed ID: 32348111 [TBL] [Abstract][Full Text] [Related]
57. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein. Behloul N; Baha S; Shi R; Meng J Virus Res; 2020 Sep; 286():198058. PubMed ID: 32531235 [TBL] [Abstract][Full Text] [Related]
58. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199 [TBL] [Abstract][Full Text] [Related]
59. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278 [TBL] [Abstract][Full Text] [Related]
60. SARS-CoV, Mers-CoV and COVID-19: what differences from a dermatological viewpoint? Rongioletti F J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):e581-e582. PubMed ID: 32526085 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]